Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7666232 | 0.95 | ALDH1A1 (0.34) | ACHEDGAT1ALDH1A1 | |
| SCHEMBL7674108 | 0.93 | ACHE (0.35) | ACHEDGAT1 | |
| SCHEMBL7671091 | 0.89 | ACHE (0.37) | ACHEDGAT1KDM4E | |
| SCHEMBL7670135 | 0.87 | PTGIR (0.33) | ACHE | |
| SCHEMBL7664228 | 0.87 | ACHE (0.38) | ACHEDGAT1 | |
| SCHEMBL7531066 | 0.86 | ACHE (0.38) | ACHEKDM4EALDH1A1GAA | |
| SCHEMBL7528229 | 0.83 | ALDH1A1 (0.34) | ACHEKDM4EALDH1A1GAA | |
| SCHEMBL7663626 | 0.83 | GAA (0.35) | KDM4EALDH1A1GAA | |
| SCHEMBL7672127 | 0.83 | PTGIR (0.33) | ACHEALDH1A1 | |
| SCHEMBL7666071 | 0.82 | SMN1; SMN2 (0.37) | KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455560-B1 | SUBSTITUTED (1-((3-ISOXAZOLIN-5-YL)CARBONYL/METHYL) -4-PIPERIDINYL) ACETIC ACID FOR USE IN INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | claimed |
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | claimed |
| US-6455560-B1 | SUBSTITUTED (1-((3-ISOXAZOLIN-5-YL)CARBONYL/METHYL) -4-PIPERIDINYL) ACETIC ACID FOR USE IN INHIBITING THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS AND FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-24 | — | — | US | disclosed |
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-6319937-B1 | INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR TREATMENT OF THROMBOEMBOLIC DISORDERS. | DUPONT PHARMACEUTICALS COMPANY | 2001-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082253-A1 | Novel isoxazoline fibrinogen receptor antagonists | FGB, F2, F13B | ACHE 3169/4885DGAT1 3596/4885KDM4E 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.